One large AZ shareholder has avoided taking sides in the should they or shouldn't they cut a deal with Pfizer debate. Instead, Richard Buxton at Old Mutual Global Investors says that AZ's top dogs ought to tie their compensation to the deal price that Pfizer just offered. His reasoning? If AZ's senior management and the board are so certain that they can outperform Pfizer's offer as an independent entity, they should be willing to tie their compensation to it. Brilliant if you ask me.
Now let's ask the AZ management what they plan to actually do? That's up to you AZ shareholders. See Fierce Pharma.
Posted by Bruce Lehr May 22nd 2014.